The phrase "adequate switching" is correct and usable in written English.
It can be used in contexts related to technology, communication, or processes where a sufficient level of change or transition is required.
Example: "The system requires adequate switching between different modes to ensure optimal performance."
Alternatives: "sufficient switching" or "proper switching".
We hypothesized that OCD patients along with slower switching performance, will have difficulties in inhibiting previously adequate switching responses, making more false alarm type errors.
Even though these switched air gap capacitors have a rather low capacitance ratio of around 5 6, they can still form adequate switching devices and RF-circuits by making use of properly designed transmission lines and when combined with high-Q inductors.
Therefore, it is important to minimize the delay imbalance between the transmitter and receiver parts of the RF subsystem so that an adequate switching point can be found.
This may contribute to an adequate switch between fatty acid and glucose substrate use under postprandial conditions and is of importance for the maintenance of normal glucose tolerance.
We excluded patients with endocarditis, as the recommended intravenous treatment is at least 4 weeks, surgical site infection following spine surgery because a 2-week intravenous antibiotic course after extensive debridement is generally considered to be adequate before switching to an oral regimen [ 14, 15] and spinal implants or tuberculous VO because of the longer treatment duration [ 16, 17].
In experiments, McCaughan demonstrated that currents even smaller than those found in Josephson-junction devices were adequate to switch the nTron from a conductive to a nonconductive state.
With the introduction of biosimilars of anticancer monoclonal antibodies (mAbs) in oncology, physicians are potentially confronted with the question whether it is clinically adequate to switch patients who are clinically stable on treatment with the reference product to a newly available biosimilar (or vice versa/from 1 biosimilar to another).
[ 22] Given that biosimilars are similar to but not identical to their originators, there is no scientific basis to substitute a biosimilar for a branded product, and automatic substitution could potentially put patients at risk by preventing adequate traceability or encouraging switching between products.
For example our CDSS failed to compute an adequate dosage regimen after switching "Metoprolol 100 retard 1A Pharma" (containing 78.09 mg metoprolol) to "Beloc-Zok Retardtabl" (containing 77.82 mg metoprolol) because of slightly differing drug strengths, whose clinical irrelevance is easily recognised by an expert but requires proper specification for consideration by a computer system.
However, neither by themselves may be adequate representations in the presence of switching disturbance patterns that are typically witnessed in process industries.
In the case of breakthrough disease activity despite a full and adequate course of a first-line preparation, switching to natalizumab, fingolimod or alemtuzumab should be considered.
